JP2019523221A5 - - Google Patents

Download PDF

Info

Publication number
JP2019523221A5
JP2019523221A5 JP2018561225A JP2018561225A JP2019523221A5 JP 2019523221 A5 JP2019523221 A5 JP 2019523221A5 JP 2018561225 A JP2018561225 A JP 2018561225A JP 2018561225 A JP2018561225 A JP 2018561225A JP 2019523221 A5 JP2019523221 A5 JP 2019523221A5
Authority
JP
Japan
Prior art keywords
sequence
antibody
seq
antibody according
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018561225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523221A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/034681 external-priority patent/WO2017205742A1/en
Publication of JP2019523221A publication Critical patent/JP2019523221A/ja
Publication of JP2019523221A5 publication Critical patent/JP2019523221A5/ja
Priority to JP2022023569A priority Critical patent/JP7331179B2/ja
Withdrawn legal-status Critical Current

Links

JP2018561225A 2016-05-27 2017-05-26 抗ｃｄ４０抗体とその使用 Withdrawn JP2019523221A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022023569A JP7331179B2 (ja) 2016-05-27 2022-02-18 抗ｃｄ４０抗体とその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662342417P 2016-05-27 2016-05-27
US62/342,417 2016-05-27
PCT/US2017/034681 WO2017205742A1 (en) 2016-05-27 2017-05-26 Anti-cd40 antibodies and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022023569A Division JP7331179B2 (ja) 2016-05-27 2022-02-18 抗ｃｄ４０抗体とその使用

Publications (2)

Publication Number Publication Date
JP2019523221A JP2019523221A (ja) 2019-08-22
JP2019523221A5 true JP2019523221A5 (enExample) 2020-07-02

Family

ID=59014833

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018561225A Withdrawn JP2019523221A (ja) 2016-05-27 2017-05-26 抗ｃｄ４０抗体とその使用
JP2022023569A Active JP7331179B2 (ja) 2016-05-27 2022-02-18 抗ｃｄ４０抗体とその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022023569A Active JP7331179B2 (ja) 2016-05-27 2022-02-18 抗ｃｄ４０抗体とその使用

Country Status (35)

Country Link
US (8) US10519243B2 (enExample)
EP (2) EP3464361B1 (enExample)
JP (2) JP2019523221A (enExample)
KR (2) KR20220028143A (enExample)
CN (1) CN109476750B (enExample)
AR (2) AR108611A1 (enExample)
AU (1) AU2017271602A1 (enExample)
BR (1) BR112018074468A2 (enExample)
CA (1) CA3025347A1 (enExample)
CL (1) CL2018003366A1 (enExample)
CO (1) CO2018012699A2 (enExample)
CR (1) CR20180605A (enExample)
CY (1) CY1124806T1 (enExample)
DO (1) DOP2018000258A (enExample)
EC (1) ECSP18094829A (enExample)
ES (1) ES2901722T3 (enExample)
HR (1) HRP20211882T1 (enExample)
HU (1) HUE056670T2 (enExample)
IL (1) IL263223B2 (enExample)
LT (1) LT3464361T (enExample)
MX (1) MX393455B (enExample)
MY (1) MY195442A (enExample)
NZ (1) NZ748644A (enExample)
PE (1) PE20190970A1 (enExample)
PH (1) PH12018502456A1 (enExample)
PL (1) PL3464361T3 (enExample)
PT (1) PT3464361T (enExample)
RS (1) RS62726B1 (enExample)
RU (1) RU2752049C2 (enExample)
SG (2) SG10201914132RA (enExample)
SI (1) SI3464361T1 (enExample)
SM (1) SMT202100721T1 (enExample)
TW (2) TWI761348B (enExample)
UA (1) UA123111C2 (enExample)
WO (1) WO2017205742A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2214701T (pt) * 2007-11-01 2016-11-02 Univ Guelph Composições e métodos de potenciar respostas imunes a eimeria
UA123111C2 (uk) * 2016-05-27 2021-02-17 Еббві Байотерапьютікс Інк. Антитіло до cd40 та його застосування
CN112512572B (zh) * 2018-04-20 2024-12-10 礼进生物医药科技（上海）有限公司 抗cd40抗体及其用途
MA55132A (fr) 2018-11-23 2022-03-02 Strike Pharma Ab Conjugués bi-spécifiques
BR112021009835A2 (pt) * 2018-11-30 2021-08-17 Jiangsu Hengrui Medicine Co., Ltd. anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
US10570210B1 (en) * 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
CN111454361B (zh) * 2019-03-04 2021-03-02 北京天广实生物技术股份有限公司 与cd40结合的抗体及其用途
EP3947454A1 (en) 2019-03-27 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
CN113728008B (zh) * 2019-04-10 2024-04-09 南开大学 抗cd40抗体及其用途
GB201910900D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
US20220370418A1 (en) 2019-09-09 2022-11-24 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
CA3148890A1 (en) * 2019-09-11 2021-03-18 Novartis Ag A method for preventing human virus associated disorders in patients
JP2022553108A (ja) * 2019-10-23 2022-12-21 リビジェン バイオファーマ ホールディングス リミテッド 抗ｃｄ４０結合分子およびそのようなものを含む二重特異性抗体
EP4056592A4 (en) * 2019-11-08 2024-03-20 Jiangsu Simcere Pharmaceutical Co., Ltd. ANTIBODY AGAINST HUMAN PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) AND USE THEREOF
EP4069291A1 (en) 2019-12-03 2022-10-12 Evotec International GmbH Interferon-associated antigen binding proteins and uses thereof
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
US20230346966A1 (en) * 2020-07-23 2023-11-02 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof in treating muscle atrophy
CN115403670B (zh) * 2021-05-26 2026-03-10 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
CA3257929A1 (en) * 2022-05-31 2025-04-22 Futuregen Biopharmaceutical (Beijing) Co., Ltd. Anti-CD40 antibodies, bispecific anti-PD-L1×CD40 antibodies, and their use
CA3262796A1 (en) * 2022-09-20 2024-03-28 Currus Biologics Pty Ltd Bispecific Polypeptides and Their Uses
AR131856A1 (es) * 2023-02-16 2025-05-07 Sanofi Sa Proteínas de unión a cd40

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
TR199902553T2 (xx) 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DE69938054T2 (de) 1998-11-18 2009-02-12 Genentech, Inc., South San Francisco Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
AU2001236621B2 (en) 2000-02-01 2006-06-15 Mycenax Biotech Inc. Cd40-binding apc-activating molecules
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
KR101223373B1 (ko) * 2003-12-25 2013-01-16 교와 핫꼬 기린 가부시키가이샤 항 ｃｄ４０ 항체의 변이체
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
US20080287309A1 (en) * 2004-07-10 2008-11-20 Alexion Pharmaceuticals, Inc. Methods for Discovering Antibodies Specific to Cancer Cells and Antibodies Discovered Thereby
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
JP5401314B2 (ja) * 2006-09-08 2014-01-29 メディミューン，エルエルシー ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用
EP2205631B1 (en) * 2007-10-05 2016-11-23 Genentech, Inc. Methods and compositions for diagnosis and treatment of amyloidosis
NZ602020A (en) * 2010-03-31 2014-05-30 Boehringer Ingelheim Int Anti-cd40 antibodies
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
SG11201500873XA (en) * 2012-08-24 2015-04-29 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc region variant
CN104918957B (zh) * 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
BR112015022119A2 (pt) * 2013-03-15 2017-08-29 Abbvie Biotherapeutics Inc Polipeptídeo, composto conjugado, composição farmacêutica, ácido nucleico, vetor, células hospedeiras procariótica e eucariótica, método de produção de um polipeptídeo, e, método de tratamento
GB201322583D0 (en) 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
HUE054075T2 (hu) 2014-10-29 2021-08-30 Seagen Inc CD40 elleni nem fukozilált antitestek adagolása és bevitele
RU2715597C2 (ru) * 2015-05-29 2020-03-02 Эббви Инк. Антитела к cd40 и способы их применения
KR20190014525A (ko) * 2016-05-27 2019-02-12 애브비 바이오테라퓨틱스 인크. 면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질
UA123111C2 (uk) * 2016-05-27 2021-02-17 Еббві Байотерапьютікс Інк. Антитіло до cd40 та його застосування

Similar Documents

Publication Publication Date Title
JP2020504101A5 (enExample)
RU2018146533A (ru) Антитела к cd40 и пути их применения
JP2019533989A5 (ja) 抗ｐｄ−１抗体及びその使用
JP2012254092A5 (enExample)
JP2017114866A5 (enExample)
JP2018121657A5 (enExample)
JP2016196468A5 (enExample)
JP2012116856A5 (enExample)
AR105026A1 (es) ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
JP2018536393A5 (enExample)
JP2013538057A5 (enExample)
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2019524645A5 (enExample)
JP2016511750A5 (enExample)
JP2015535828A5 (enExample)
JP2020018311A5 (enExample)
JP2019527047A5 (enExample)
FI3390442T3 (fi) Anti-C5-vasta-aineita ja käyttömenetelmiä
JP2018504105A5 (enExample)
RU2019110835A (ru) Антитела к pd-1(cd279)
JP2015146822A5 (enExample)
JP2018521638A5 (enExample)
JP2017176174A5 (enExample)
JP2014237714A5 (enExample)
JP2017522888A5 (enExample)